Annette Juul Vangsted

Annette Juul Vangsted

Auto-generated profile, based on publicly available information

Annette Juul Vangsted

Department of Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2010 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MBM. K. Brimnes
M. K. Brimnes
AVA. J. Vangsted
A. J. Vangsted
LKL. M. Knudsen
L. M. Knudsen
PGP. Gimsing
P. Gimsing
AGA. O. Gang
A. O. Gang
Inge MarieInge Marie
Inge Marie

1 July 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJonathan S. Mitchell
Jonathan S. Mitchell
NLNi Li
Ni Li
NWNiels Weinhold
Niels Weinhold
AFAsta Försti
Asta Försti
MAMina Ali
Mina Ali
Richard HoulstonRichard Houlston
Richard Houlston
Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P=1.31 × 10−8), 6q21 (rs9372120, P=9.09 × 10−15), 7q36.1 (rs7781265, P=9.71 × 10−9), 8q24.21 (rs1948915, P=4.20 × 10−11), 9p21.3 (rs2811710, P=1.72 × 10−13), 10p12.1 (rs2790457, P=1.77 × 10−8), 16q23.1 (rs7193541, P=5.00 × 10−12) and 20q13.13 (rs6066835, P=1.36 × 10−13), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development.

22 May 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
Evangelos TerposEvangelos Terpos
Evangelos Terpos
MEMonika Engelhardt
Monika Engelhardt
GCGordon Cook
Gordon Cook
FGFrancesca Gay
Francesca Gay
María Victoria MateosMaría Victoria Mateos
María Victoria Mateos
PSPieter Sonneveld
Pieter Sonneveld

1 October 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
PGPeter Gimsing
Peter Gimsing
KCKristina Carlson
Kristina Carlson
ITIngemar Turesson
Ingemar Turesson
PFPeter Fayers
Peter Fayers
AWAnders Waage
Anders Waage
FWFinn Wisløff
Finn Wisløff

26 May 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBhairavi Swaminathan
Bhairavi Swaminathan
GTGuðmar Thorleifsson
Guðmar Thorleifsson
MJMagnus Jöud
Magnus Jöud
MAMina Ali
Mina Ali
EJEllinor Johnsson
Ellinor Johnsson
BNBjörn Nilsson
Björn Nilsson
Multiple myeloma (MM) is characterized by an uninhibited, clonal growth of plasma cells. While first-degree relatives of patients with MM show an increased risk of MM, the genetic basis of inherited MM susceptibility is incompletely understood. Here we report a genome-wide association study in the Nordic region identifying a novel MM risk locus at ELL2 (rs56219066T; odds ratio (OR)=1.25; P=9.6 × 10−10). This gene encodes a stoichiometrically limiting component of the super-elongation complex that drives secretory-specific immunoglobulin mRNA production and transcriptional regulation in plasma cells. We find that the MM risk allele harbours a Thr298Ala missense variant in an ELL2 domain required for transcription elongation. Consistent with a hypomorphic effect, we find that the MM risk allele also associates with reduced levels of immunoglobulin A (IgA) and G (IgG) in healthy subjects (P=8.6 × 10−9 and P=6.4 × 10−3, respectively) and, potentially, with an increased risk of bacterial meningitis (OR=1.30; P=0.0024).

10 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
NBNizar J. Bahlis
Nizar J. Bahlis
RBRachid Baz
Rachid Baz
SHSimon J. Harrison
Simon J. Harrison
HQHang Quach
Hang Quach
SHShir-Jing Ho
Shir-Jing Ho
JKJonathan L. Kaufman
Jonathan L. Kaufman
PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents including bortezomib, dexamethasone, and daratumumab. METHODS: This phase I study ( NCT03314181 ) evaluated venetoclax with daratumumab and dexamethasone (VenDd) in patients with t(11;14) RRMM and VenDd with bortezomib (VenDVd) in cytogenetically unselected patients with RRMM. Primary objectives included expansion-phase dosing, safety, and overall response rate. Secondary objectives included further safety analysis, progression-free survival, duration of response, time to progression, and minimal residual disease negativity. RESULTS: Forty-eight patients were enrolled, 24 each in parts 1 (VenDd) and 2 (VenDVd). There was one dose-limiting toxicity in part 1 (grade 3 febrile neutropenia, 800 mg VenDd). Common adverse events with VenDd and VenDVd included diarrhea (63% and 54%) and nausea (50% and 50%); grade ≥ 3 adverse events were observed in 88% in the VenDd group and 71% in the VenDVd group. One treatment-emergent death occurred in part 2 (sepsis) in the context of progressive disease, with no other infection-related deaths on study with medians of 20.9 and 20.4 months of follow-up in parts 1 and 2, respectively. The overall response rate was 96% with VenDd (all very good partial response or better [≥ VGPR]) and 92% with VenDVd (79% ≥ VGPR). The 18-month progression-free survival rate was 90.5% (95% CI, 67.0 to 97.5) with VenDd and 66.7% (95% CI, 42.5 to 82.5) with VenDVd. CONCLUSION: VenDd and VenDVd produced a high rate of deep and durable responses in patients with RRMM. These results support continued evaluation of venetoclax with daratumumab regimens to treat RRMM, particularly in those with t(11;14).